ACOG
Alpha Cognition·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ACOG
Alpha Cognition Inc.
A pre commercial biopharmaceutical company dedicated to developing treatment methods for patients with neurodegenerative diseases such as Alzheimer's disease
1452 Hughes Rd. Ste. 200 , Grapevine, Texas 76051
--
Alpha Cognition Inc., incorporated under the British Columbia Business Corporations Act (" BCBCA ") on November 15, 2017 as "Crystal Bridge Enterprises Inc.", is a Canadian capital associate. On March 18, 2021, they completed a qualifying transaction with Alpha Cognition Canada Inc., and changed its name to Alpha Cogning Co., Ltd. Alpha Cognition, Inc., is a pre-commercialization stage biopharmaceutical company developing treatments for patients with neurodegenerative diseases such as Alzheimer's disease.
Earnings Call
Q2/2025
Estimate EPS-0.55
Actual EPS-0.65
Estimate Revenue1.65M
Actual Revenue1.66M
Alpha Cognition's 2025 Q2 Earnings Call: Unpacking Key Contradictions in Patient Penetration, Discounting, and Financial Guidance
Aug 14,2025 11:00
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ACOG has released its 2025 Q2 earnings. EPS was reported at -0.65, versus the expected -0.55, missing expectations. The chart below visualizes how ACOG has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ACOG has released its 2025 Q3 earnings report, with revenue of 2.84M, reflecting a YoY change of NaN%, and net profit of -1.32M, showing a YoY change of 29.13%. The Sankey diagram below clearly presents ACOG's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
